key: cord-0863975-hcz44oks
authors: Fourati, Slim; Bailly, Benoit; Le Bouter, Anne; Guilpain, Luc; Rodriguez, Christophe; Pawlotsky, Jean-Michel
title: Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-CoV-2 variant B.1.351 (β) in an elderly nursing home
date: 2021-08-03
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab676
sha: a38e52718c337a867f91d57c4020d9d66d2268f7
doc_id: 863975
cord_uid: hcz44oks

nan

We further investigated the anti-SARS-CoV-2 immune response in our vaccinated cohort, comparing anti-SARS CoV-2 antibody levels in non-infected versus infected residents. Anti-SARS-CoV-2 IgG antibodies targeting the spike RBD antigen were sought by means of the Abbott IgG anti-S kit (Abbott Diagnostics, Lake Forest, Illinois). All vaccinated residents were tested for anti-S antibodies within 1 to 2 months and a half after the second dose of vaccine. Those who were infected were tested within 9 days after the outbreak started (i.e. within 4 days after symptom onset in symptomatic residents). Overall, the levels of anti-S antibodies did not differ between those who were infected (n=13) and those who were not (n=13): median 1069 AU/mL (range <6.8-8188 AU/mL) vs median 1481 AU/mL (range 448-2928 AU/mL), respectively (p=0.76: Figure 1 ). The anti-S antibody levels did not significantly differ between vaccinated patients with a severe vs non-severe infection.

However, the 2 infected vaccinated residents who died from the infection had relatively low antibody levels one month after the second vaccine dose (139 and 643 AU/mL, respectively).

A high level of anti-S antibodies (>1000 AU/mL) has been associated with in vitro viral neutralization of all major circulating variants of concern, including variant B.1.1.7 (α) (3) . Larger observational studies are needed to confirm this hypothesis.

BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity

Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home

SARS

CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. medRxiv. 17 mai 2021

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

A c c e p t e d M a n u s c r i p t Funding source: None

S.F. has served as a paid speaker for Abbvie and Abbott diagnostics and has served on an advisory board/DSMB for MSD, outside the submitted work. C.R. has served as an advisor, and/or speaker for Illumina, and Vela Diagnostics. J.-M.P. has served as a paid advisor, and/or speaker for Abbvie, Gilead, GlaxoSmithKline, Merck, Regulus, and Siemens Healthcare. N.D. The remaining authors have no conflict of interest to disclose. A c c e p t e d M a n u s c r i p t Figure 1